175 related articles for article (PubMed ID: 38240863)
21. Anti-GD2 immunotherapy for neuroblastoma.
Sait S; Modak S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
[TBL] [Abstract][Full Text] [Related]
23. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy with anti-G
Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
[TBL] [Abstract][Full Text] [Related]
25. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
[TBL] [Abstract][Full Text] [Related]
26. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
Nazha B; Inal C; Owonikoko TK
Front Oncol; 2020; 10():1000. PubMed ID: 32733795
[TBL] [Abstract][Full Text] [Related]
27. Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain.
Liu XY; Chen YL; Liu GJ; Deng XN; Cui Y; Tan J; Dong XC; Li HY; Chen GJ; Ou ZM; Wang CH
FEBS Open Bio; 2022 Sep; 12(9):1644-1656. PubMed ID: 35792784
[TBL] [Abstract][Full Text] [Related]
28. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
29. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
30. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
Chen RL; Reynolds CP; Seeger RC
Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
[TBL] [Abstract][Full Text] [Related]
31. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
[TBL] [Abstract][Full Text] [Related]
32. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
33. SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma.
Chen X; Kunda PE; Lin J; Zhou M; Huang J; Zhang H; Liu T
J Cancer Res Clin Oncol; 2018 Apr; 144(4):675-684. PubMed ID: 29372378
[TBL] [Abstract][Full Text] [Related]
34. Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.
Belounis A; Ayoub M; Cordeiro P; Lemieux W; Teira P; Haddad E; Herblot S; Duval M
Cancer Immunol Immunother; 2020 Sep; 69(9):1767-1779. PubMed ID: 32342128
[TBL] [Abstract][Full Text] [Related]
35. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
36. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
37.
McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.
Keyel ME; Reynolds CP
Biologics; 2019; 13():1-12. PubMed ID: 30613134
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
40. GD2-targeted immunotherapy and radioimmunotherapy.
Dobrenkov K; Cheung NK
Semin Oncol; 2014 Oct; 41(5):589-612. PubMed ID: 25440605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]